TELA Bio Expects Full Year 2024 Revenue Of $74M-$76M, Representing 27%-30% Y/Y Growth; Est $75.196M
$TELA
Medical/Dental Instruments
Health Care
TELA Bio Expects Full Year 2024 Revenue Of $74M-$76M, Representing 27%-30% Y/Y Growth; Est $75.196M
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/31/2022 | $17.00 | Buy | Lake Street |
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
Lake Street initiated coverage of TELA Bio with a rating of Buy and set a new price target of $17.00
MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leader
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines. "Greg has been an instrumental player in the TELA Bio story, supporting our commercial strategy and cultivating each of our key group
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his extensive expertise, especially in microvascular reconstruction and innovative approaches to complex surgical problems. Dr. Langstein previously held the position of Associate Professor of Plastic Surgery at the University of Texas MD Anderson Cancer Center, where
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
4 - TELA Bio, Inc. (0001561921) (Issuer)
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Reported revenue of $19.0 million in the third quarter, representing growth of 26% over the prior year period;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the third quarter, resulting in a year-over-year growth in unit sales volume for each product of approximately 39% and 44%, respectively;Closed on an underwritten public offering yielding gross proceeds of ap
MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,400 shares of its common stock to six newly-hired employees, with a grant date of November 1, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her
MALVERN, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced the closing of its previously announced underwritten public offering of 14,670,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares, at a price to the public of $2.25 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant, which represents the per share public offering price for the shares of com
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2024 financial results on Thursday, November 7, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before
MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Reported revenue of $16.1 million in the second quarter, representing growth of 11% over the prior year period of 2023;Appointed Greg Firestone as Chief Commercial Officer on May 20, 2024 to drive our next phase of revenue growth by enhancing sales representative training, regional supervision, and performance measurement and accountability;Launched our robotically compatible OviTex IHR Reinforced Tiss
MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Monday, August 12, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before
Canaccord Genuity analyst Caitlin Cronin maintains TELA Bio (NASDAQ:TELA) with a Buy and maintains $14 price target.
Piper Sandler analyst Matt O'Brien reiterates TELA Bio (NASDAQ:TELA) with a Overweight and lowers the price target from $12 to $10.
SC 13G - TELA Bio, Inc. (0001561921) (Subject)
SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)
SC 13D/A - TELA Bio, Inc. (0001561921) (Subject)
10-Q - TELA Bio, Inc. (0001561921) (Filer)
8-K - TELA Bio, Inc. (0001561921) (Filer)
8-K - TELA Bio, Inc. (0001561921) (Filer)